secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001213900-26-032403
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed
-----------------------------------------------------------------------------

- FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).
- NDV-01 Phase 2: 95% CR at any time, 76% durable CR at 12 months in high-risk NMIBC; BCG-unresponsive 80% CR at 12 months.
- Oversubscribed $160M PIPE closed March 2026; cash $93M at Dec 31, 2025 plus PIPE expected to fund operations through 2029.
- R&D expense $26.9M (down from $46.2M); G&A $32.2M (down from $37.7M); shares outstanding 104.9M.
- On track to start Phase 3 RESCUE program and Sepranolone Phase 2 in Prader-Willi mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/0001213900-26-032403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea0282688-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-032403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer